Literature DB >> 32877730

The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems.

Bruno Fonseca-Santos1, Marlus Chorilli2.   

Abstract

Neurological disorders have been growing in recent years and are highly prevalent globally. Resveratrol (RES) is a natural product from plant sources such as grape skins. This compound has shown biological activity in many diseases, in particular, those that act on the central nervous system. The mechanism of action and the key points in neurological disorders were described and show the targeted mechanism of action. Due to the insolubility of this compound; the use of nanotechnology-based systems has been proposed for the incorporation of RES and RES-loaded nanocarriers have been designed for intranasal administration, oral or parenteral routes to deliver it to the brain. In general, these nanosystems have shown to be effective in many studies, pharmacological and pharmacokinetic assays, as well as some cell studies. The outcomes show that RES has been reported in human clinical trials for some neurological diseases, although no studies were performed in humans using nanocarriers, animal and/or cellular models have been reported to show good results regarding therapeutics on neurological diseases. Thus, the use of this nutraceutical has shown true for neurological diseases and its loading into nanocarriers displaying good results on the stability, delivery and targeting to the brain.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood–brain barrier; Brain; Nanocarriers; Nanomedicines; Nasal drug delivery; Resveratrol

Mesh:

Substances:

Year:  2020        PMID: 32877730     DOI: 10.1016/j.ijpharm.2020.119832

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Characterization and Systemic Delivery of Dibenzoylmethane via the Intranasal Route.

Authors:  Deepal Vora; Anthony E Kincaid; Justin Tolman; Harsh Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

Review 2.  Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside.

Authors:  Fahadul Islam; Mohamed H Nafady; Md Rezaul Islam; Susmita Saha; Salma Rashid; Aklima Akter; Md Harun- Or-Rashid; Muhammad Furqan Akhtar; Asma Perveen; Ghulam Md Ashraf; Md Habibur Rahman; Sherouk Hussein Sweilam
Journal:  Mol Neurobiol       Date:  2022-05-12       Impact factor: 5.590

3.  Resveratrol Ameliorates Systemic Sclerosis via Suppression of Fibrosis and Inflammation Through Activation of SIRT1/mTOR Signaling.

Authors:  Qicen Yao; Qingchao Wu; Xiayu Xu; Yixi Xing; Jin Liang; Qianqi Lin; Meiqiong Huang; Yiling Chen; Bo Lin; Weifei Chen
Journal:  Drug Des Devel Ther       Date:  2020-12-02       Impact factor: 4.162

Review 4.  Therapeutic Effects of Natural Products on Cervical Cancer: Based on Inflammatory Pathways.

Authors:  Zi-Wei Zhou; Hui-Zhi Long; Shuo-Guo Xu; Feng-Jiao Li; Yan Cheng; Hong-Yu Luo; Li-Chen Gao
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

Review 5.  Advances in Nano-Enabled Platforms for the Treatment of Depression.

Authors:  Fadzai P Mutingwende; Pierre P D Kondiah; Philemon Ubanako; Thashree Marimuthu; Yahya E Choonara
Journal:  Polymers (Basel)       Date:  2021-04-29       Impact factor: 4.329

Review 6.  Delivery of Natural Agents by Means of Mesoporous Silica Nanospheres as a Promising Anticancer Strategy.

Authors:  Khaled AbouAitah; Witold Lojkowski
Journal:  Pharmaceutics       Date:  2021-01-22       Impact factor: 6.321

Review 7.  Resveratrol has an Overall Neuroprotective Role in Ischemic Stroke: A Meta-Analysis in Rodents.

Authors:  Jianyang Liu; Jialin He; Yan Huang; Zhiping Hu
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

Review 8.  Nanomedicine as an Emerging Technology to Foster Application of Essential Oils to Fight Cancer.

Authors:  Khaled AbouAitah; Witold Lojkowski
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.